C-reactive protein: The harbinger of cardiovascular diseases

Southern Medical Journal

Volumn 101, Issue 5, 2008, Pages 525-533

  Abi Saleh, Bernard ^a   Iskandar, Said B ^b   Elgharib, Nader ^b   Cohen, Michael V ^b  

^a UNIVERSITY OF SOUTH ALABAMA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aspirin; Atherosclerosis; High sensitivity C reactive protein; Inflammation; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BOSENTAN; C REACTIVE PROTEIN; CERIVASTATIN; DROLOXIFENE; INTERLEUKIN 6 ANTIBODY; PIOGLITAZONE; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ANGINA PECTORIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM; HEART INFARCTION; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; VALVULAR HEART DISEASE;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEART FAILURE; HEART TRANSPLANTATION; HEART VALVE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 43149112038     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31816c0195     Document Type: Review

References (90)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92(suppl 1A):10i-18i.
3. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:446-445.
4. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort study, 1984 to 1992. Circulation 1999;99:237-242.
5. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
6. Boyle JJ. Association of coronary plaque rupture and arteriosclerotic inflammation. J Pathol 1997;181:93-99.
7. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994;90:1669-1678.
8. Liuzzo G, Santamaria M, Biasucci LM, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein: evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol 2007;49:185-194.
9. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
10. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
11. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
12. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003;108:1676-1678.
13. Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off Ed) 1990;25:13, 16, 21-28.
14. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-1357.
15. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
16. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999;10:435-441.
17. de Beer FC, Soutar AK, Baltz ML, et al. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982;156:230-242.
18. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002;53:1029-1034.
19. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
20. Crawford DC, Sanders CL, Qin X, et al. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006;114:2458-2465.
21. Lange LA, Carlson CS, Hindorff LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006;296:2703-2711.
22. Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-753.
23. Kapyaho K, Welin MG, Tanner P, et al. Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest 1989;49:389-393.
24. Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-468.
25. Zhu J, Quyyumi AA, Norman JE, et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999;34:1738-1743.
26. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000;102:1917-1923.
27. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-630.
28. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001;103:45-51.
29. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-257.
30. Kähler J, Gerth S, Schäfer P, et al. Antibodies to chlamydial lipopolysaccharides in unstable angina pectoris. Am J Cardiol 2001;87:1150-1153.
31. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromycin in coronary artery disease: elimination of myocardial infarction with chlamydia (ACADEMIC) study. Circulation 1999;99:1540-1547.
32. Zhou YF, Csako G, Grayston JT, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999;84:595-598.
33. Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001;103:3062-3068.
34. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
35. Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem 2007;40:326-329.
36. Bazzino O, Ferreirós ER, Pizarro R, et al. C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. Am J Cardiol 2001;87:1235-1239.
37. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-860.
38. Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996;94:2373-2380.
39. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-2067.
40. Szmitko PE, Fedak PW, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003;107:3093-3100.
41. Oltrona L, Ardissino D, Merlini PA, et al. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol 1997;80:1002-1006.
42. Morrow D, Rifai N, Antman E, et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-1465.
43. Beattie MS, Shlipak MG, Liu H, et al. C-reactive protein and ischemia in users and nonusers of β-blockers and statins: data from the Heart and Soul study. Circulation 2003;107:245-250.
44. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and cardiovascular disease (the Health, Aging and Body Composition [Health ABC] study) Am J Cardiol 2003;92:522-528.
45. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000;140:324-328.
46. Harb TS, Zareba W, Moss AJ, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002;89:216-221.
47. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.
48. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006;70:1379-1384.
49. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
50. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29.
51. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
52. Anwaruddin S, Askari AT, Topol EJ. Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 2007;49:279-289.
53. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-619.
54. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21:1152-1158.
55. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-518.
56. Moukarbel GV, Arnaout MS, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001;24:506-510.
57. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007;195:374-378.
58. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322.
59. Rosen BD, Cushman M, Nasir K, et al. Relationship between C-reactive protein levels and regional left ventricular function in asymptomatic individuals: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2007;49:594-600.
60. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-461.
61. Hedman A, Larsson PT, Alam M, et al. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007;120:108-114.
62. Kaneko K, Kanda T, Hasegawa A, et al. C-reactive protein as a prognostic marker in lymphocytic myocarditis. Jpn Heart J 2000;41:41-47.
63. Pethig K, Heublein B, Kutschka I, et al. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 2000;102:233-236.
64. Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000;102:2100-2104.
65. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
66. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 1997;29:630-634.
67. Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-1082.
68. Sánchez PL, Santos JL, Kaski JC, et al; Grupo AORTICA (Grupo de Estudio de la Estenosis Aórtica). Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 2006;97:90-93.
69. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-135.
70. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
71. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-798.
72. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-1270.
73. Habib A, Shamseddeen I, Nasrallah MS, et al. Modulation of COX-2 expression by statins in human monocytic cells. FASEB J 2007;21:1665-1674.
74. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935.
75. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
76. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
77. Nissen SE, Tuzcu EM, Schoenhagen P, et al; For the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
78. Ridker PM, Cannon CP, Morrow D, et al; For the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
79. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002;40:49-55.
80. Shishehbor MH, Brennan M-L, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-431.
81. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherogenesis. Nature 1998;394:894-897.
82. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-58.
83. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 2007;49:290-297.
84. Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005;111:1439-1447.
85. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716.
86. Yildirir A, Aybar F, Tokgozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002;53:54-58.
87. Garcia-Moll X, Zouridakis E, Cole D, et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 2000;21:1598-1606.
88. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-4222.
89. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
90. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol 2000;35:1535-1542.